Liver transplantation for HBV-related cirrhosis in Europe: An ELTR study on evolution and outcomes

Basit Öğe Kaydı
dc.authoridRUSSO, FRANCESCO PAOLO/0000-0003-4127-8941
dc.authoridBurra, Patrizia/0000-0002-8791-191X
dc.authoridKaram, Vincent/0000-0002-7391-0190
dc.authoridSalizzoni, Mauro/0000-0002-5480-8705
dc.authoridLampertico, Pietro/0000-0002-1026-7476
dc.authoridkilic, murat/0000-0002-2887-1487
dc.authorwosidPinna, Antonio/AAC-6685-2019
dc.authorwosidRUSSO, FRANCESCO PAOLO/AAO-4597-2020
dc.authorwosidBurroughs, Andrew K/C-5645-2009
dc.authorwosidKaram, Vincent/HLQ-6211-2023
dc.authorwosidBurra, Patrizia/AAB-2448-2019
dc.authorwosidmarzano, alfredo/AAS-2988-2021
dc.authorwosidLampertico, Pietro/J-8463-2018
dc.contributor.authorBurra, Patrizia
dc.contributor.authorGermani, Giacomo
dc.contributor.authorAdam, Rene
dc.contributor.authorKaram, Vincent
dc.contributor.authorMarzano, Alfredo
dc.contributor.authorLampertico, Pietro
dc.contributor.authorSalizzoni, Mauro
dc.date.accessioned2024-08-04T20:37:23Z
dc.date.available2024-08-04T20:37:23Z
dc.date.issued2013
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground & Aims: HBV-related chronic liver disease is one of the most common indications for liver transplantation (LT) in Europe. The ELTR database was used to evaluate outcomes and evolution over 20 years (01/1988 and 12/2010). Methods: HBV transplanted patients were analysed according to indication for LT: decompensated cirrhosis (HBVdec) or hepatocellular carcinoma (HBV/HCC). These groups were compared with co-infected patients HBV/HDV (HBDV), HBV/HCV (HBCV), HBV/HDV/HCV (HBDCV); n = 16,664 and with HCV patients (n = 2452) according to LT indication. Results: 5912 patients were transplanted for HBV (78% HBVdec, 22% HBV/HCC), with HBV/HCC patients who increased from 15.8% in 1988-1995 to 29.6% in 2006-2010 (p <0.001). In HBVdec patients, 1, 3, 5, and 10 year patient and graft survival was 83%, 78%, 75%, 68%, and 80%, 74%, 71%, 64%, respectively, significantly better than HBV/HCC (84%, 73%, 68%, 61%, and 81%, 70%, 65%, 58% respectively; p = 0.001 and p = 0.026). In 2006-2010 patient and graft survival significantly improved compared to 1988-1995, both for HBVdec and HBV/HCC (each p <0.001). A better patient and graft survival was seen in HBV/HCC patients with HBV-DNA(-) compared to HBV-DNA(+) at the time of LT (p <0.001). Disease recurrence, as cause of death/graft loss, was significantly reduced in recent years compared to the past: currently <1% for HBVdec and 3% for HBV/HCC. Conclusions: Outcomes of LT for HBV have improved in recent years, with disease recurrence being no longer a significant cause of death/graft loss. HBV-DNA at the time of LT seems to influence survival only in HBV/HCC patients. (C) 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.en_US
dc.identifier.doi10.1016/j.jhep.2012.10.016
dc.identifier.endpage296en_US
dc.identifier.issn0168-8278
dc.identifier.issue2en_US
dc.identifier.pmid23099188en_US
dc.identifier.scopus2-s2.0-84872423212en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage287en_US
dc.identifier.urihttps://doi.org/10.1016/j.jhep.2012.10.016
dc.identifier.urihttps://hdl.handle.net/11616/95926
dc.identifier.volume58en_US
dc.identifier.wosWOS:000315069900014en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Bven_US
dc.relation.ispartofJournal of Hepatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLiver transplantationen_US
dc.subjectHepatitis Ben_US
dc.subjectEuropeen_US
dc.titleLiver transplantation for HBV-related cirrhosis in Europe: An ELTR study on evolution and outcomesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu